Regeneron's Eylea boosts sight in those with diabetic ailment

|About: Regeneron Pharmaceuticals... (REGN)|By:, SA News Editor

Regeneron Pharmaceuticals' (REGN) Eylea treatment was significantly more successful than laser surgery in improving the vision of patients with diabetic macular edema (DME) in two Phase III trials.

DME is the leading cause of blindness in younger and middle-aged adults; Eylea could potentially treat over 6M patients globally.

Regeneron intends to apply for FDA approval of Eylea to treat DME in 2013, a year ahead of plan. Bayer, which sells the drug outside the U.S., will apply for EU authorization.

Eyelea is already used in patients with wet age-related macular edema, the leading cause of blindness among the elderly. (PR)

Regeneron earnings